...Takeda said it returned its Japanese rights to fulranumab ( AMG 403 ) and trebananib ( AMG... ...April, Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) said it discontinued Phase III testing of fulranumab...
...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it returned its Japanese rights to fulranumab ( AMG 403... ...Inc. (NASDAQ:AMGN). In April, Johnson & Johnson (NYSE:JNJ) said it discontinued Phase III development of fulranumab...
...& Johnson said it will discontinue its Phase III development program for osteoarthritis pain candidate fulranumab... ...outside of Japan from Amgen under a 2008 deal, will return all rights to Amgen. Fulranumab...
...& Johnson (NYSE:JNJ) said it will discontinue its Phase III development program for fulranumab ( AMG 403... ...studies. Janssen paid $50 million up front in 2008 for exclusive, worldwide ex-Japan rights to fulranumab...
...as interstitial cystitis or chronic pancreatitis. Tanezumab was in Phase III testing for OA pain, fulranumab... ...products with demonstrated analgesic efficacy, such as interstitial cystitis or chronic pancreatitis. Product: Fulranumab ( AMG 403... ...placed clinical holds on 3 mAbs against NGF due to safety concerns for the class: fulranumab...
...holds on three mAbs against NGF due to safety concerns for the class: fulranumab ( AMG 403... ...and tanezumab from Pfizer Inc. (NYSE:PFE). Tanezumab was in Phase III testing for OA pain, fulranumab...
...holds on three anti-NGF pain candidates due to safety concerns for the class: fulranumab ( AMG 403... ...from Pfizer. Last May, FDA lifted a clinical hold on a Phase II trial of fulranumab...
...at least three anti-NGF pain candidates due to safety concerns for the class: fulranumab ( AMG 403... ...Inc. (NYSE:PFE). In May, FDA lifted a clinical hold on a Phase II trial of fulranumab...
